靶向细胞外基质硬度以减轻疾病:从分子机制到临床试验
本文综述了细胞外基质(ECM)硬度在衰老及癌症、纤维化、心血管疾病进展中的作用,指出ECM硬度是驱动疾病进展的重要机械线索。文章讨论了通过预防或逆转组织硬化或中断细胞响应来靶向ECM力学的治疗策略,并总结了主要驱动因素(如肌成纤维细胞转化、TGFβ、基质交联)及临床潜在药物干预。
要点
- ECM硬度是衰老及癌症、纤维化、心血管疾病进展中的突出机械线索。
- 靶向ECM力学可通过预防或逆转组织硬化或中断细胞响应实现。
- 主要驱动因素包括表型转化的肌成纤维细胞、TGFβ和基质交联。
核心结论
- 靶向细胞外基质力学(预防或逆转组织硬化或中断细胞响应)是具有临床潜力的治疗策略。
研究设计与样本
- 综述性文章,讨论靶向组织硬化的治疗干预及其局限性、临床前药物开发和临床试验。
主要发现
- 细胞外基质硬度是驱动疾病进展的突出机械线索,通过改变细胞行为发挥作用。
- 主要驱动因素包括表型转化的肌成纤维细胞、转化生长因子β(TGFβ)和基质交联。
- 克服细胞外基质硬化的潜在药理学干预正在临床涌现。
临床怎么用
- 可考虑通过预防或逆转组织硬化或中断细胞对基质硬度的下游响应来靶向细胞外基质力学。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tissues stiffen during aging and during the pathological progression of cancer, fibrosis, and cardiovascular disease. Extracellular matrix stiffness is emerging as a prominent mechanical cue that precedes disease and drives its progression by altering cellular behaviors. Targeting extracellular matrix mechanics, by preventing or reversing tissue stiffening or interrupting the cellular response, is a therapeutic approach with clinical potential. Major drivers of changes to the mechanical properties of the extracellular matrix include phenotypically converted myofibroblasts, transforming growth factor β (TGFβ), and matrix cross-linking. Potential pharmacological interventions to overcome extracellular matrix stiffening are emerging clinically. Aside from targeting stiffening directly, alternative approaches to mitigate the effects of increased matrix stiffness aim to identify and inhibit the downstream cellular response to matrix stiffness. Therapeutic interventions that target tissue stiffening are discussed in the context of their limitations, preclinical drug development efforts, and clinical trials.
引用
- Lampi MC, Reinhart-King CA. Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials. Sci Transl Med. 2018. PMID: 29298864. doi:10.1126/scitranslmed.aao0475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。